Preventing bone loss in ICU patients with anti-bone drugs
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This Phase 2 study tests whether zoledronic acid or denosumab can prevent bone thinning in critically ill adults after staying in the ICU. It may help reduce the risk of future bone fractures if your body is at higher risk during and after critical illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 50+ or a man age 70+
- You have been in the ICU for 2 or more days and are not expected to leave the ICU on day 2
- You needed strong ICU breathing or blood-pressure support for at least 6 total hours (for example, a ventilator or high oxygen/oxygen support)
- Doctors expect you to survive this current hospital stay
- You do not have certain bone diseases like multiple myeloma, metastatic bone cancer, or Paget’s disease
- Your kidneys are strong enough (estimated kidney filter rate is at least 30) and you are not on kidney support dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an osteoporosis medication can help preserve muscle strength in older adults who live in senior facilities. It's for people age 65+ with fragile bones or low bone density who are at risk for falls and fractures.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This study tests whether denosumab, a medication given as an injection, can help prevent broken bones in people with type 2 diabetes who are at high risk for fractures. It aims to see if this treatment can strengthen bones and reduce fracture risk.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
Hear when a new Critical Illness trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.